CN116916950A - 包含Sbi佐剂的组合物及其使用方法 - Google Patents

包含Sbi佐剂的组合物及其使用方法 Download PDF

Info

Publication number
CN116916950A
CN116916950A CN202280016257.9A CN202280016257A CN116916950A CN 116916950 A CN116916950 A CN 116916950A CN 202280016257 A CN202280016257 A CN 202280016257A CN 116916950 A CN116916950 A CN 116916950A
Authority
CN
China
Prior art keywords
antigen
fragment
fusion
polypeptide
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280016257.9A
Other languages
English (en)
Chinese (zh)
Inventor
K·巴克曼
N·达尔
N·叶罗申科
T·吉尔
K·贾梅
M·凯维尼
J·奎因
H·拉亚涅米
E·韦伯斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helical Nanotechnology Co
Original Assignee
Helical Nanotechnology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helical Nanotechnology Co filed Critical Helical Nanotechnology Co
Priority to CN202411062411.3A priority Critical patent/CN119161490A/zh
Publication of CN116916950A publication Critical patent/CN116916950A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202280016257.9A 2021-03-04 2022-03-03 包含Sbi佐剂的组合物及其使用方法 Pending CN116916950A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411062411.3A CN119161490A (zh) 2021-03-04 2022-03-03 包含Sbi佐剂的组合物及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156860P 2021-03-04 2021-03-04
US63/156,860 2021-03-04
PCT/US2022/018610 WO2022187424A1 (en) 2021-03-04 2022-03-03 Compositions including sbi adjuvants and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411062411.3A Division CN119161490A (zh) 2021-03-04 2022-03-03 包含Sbi佐剂的组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN116916950A true CN116916950A (zh) 2023-10-20

Family

ID=80820175

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280016257.9A Pending CN116916950A (zh) 2021-03-04 2022-03-03 包含Sbi佐剂的组合物及其使用方法
CN202411062411.3A Pending CN119161490A (zh) 2021-03-04 2022-03-03 包含Sbi佐剂的组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411062411.3A Pending CN119161490A (zh) 2021-03-04 2022-03-03 包含Sbi佐剂的组合物及其使用方法

Country Status (11)

Country Link
US (3) US11771758B2 (https=)
EP (1) EP4301404A1 (https=)
JP (2) JP2024508683A (https=)
KR (1) KR20230154048A (https=)
CN (2) CN116916950A (https=)
AU (2) AU2022228575C1 (https=)
BR (1) BR112023017749A2 (https=)
CA (1) CA3211083A1 (https=)
IL (2) IL320523A (https=)
MX (1) MX2023009995A (https=)
WO (1) WO2022187424A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060631A1 (en) * 2017-09-20 2019-03-28 Helix Nanotechnologies, Inc. EXPRESSION SYSTEMS THAT FACILITATE THE DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE
CA3211083A1 (en) 2021-03-04 2022-09-09 Kyle BACKMAN Compositions including sbi adjuvants and methods of use thereof
WO2025137486A1 (en) 2023-12-22 2025-06-26 Helix Nanotechnologies Inc Cap compounds and rnas comprising the same
US20250270299A1 (en) * 2024-01-31 2025-08-28 Helix Nanotechnologies Inc Methods of using compositions comprising sbi domains
WO2025166067A1 (en) 2024-01-31 2025-08-07 Helix Nanotechnologies, Inc. Sars-cov-2 vaccine compositions and methods
WO2026015884A1 (en) 2024-07-11 2026-01-15 Helix Nanotechnologies Inc Compositions comprising ire-1 binding sequences and uses thereof
WO2026084768A1 (en) 2024-10-16 2026-04-23 Helix Nanotechnologies Inc Helper proteins for increased secretion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1209455A (zh) * 1997-06-23 1999-03-03 辉瑞大药厂 编码纤溶酶原激活蛋白的dna
WO2002072792A2 (en) * 2001-03-13 2002-09-19 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
CN1374871A (zh) * 1999-07-21 2002-10-16 利思进药品公司 增强蛋白和肽抗原免疫原性的Fc融合蛋白
CN101448854A (zh) * 2006-03-22 2009-06-03 免疫生物学有限公司 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白
WO2018096089A1 (en) * 2016-11-25 2018-05-31 The University Of Bath Immunogenic compositions comprising sbi protein and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610776D0 (en) 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
GB201016403D0 (en) 2010-09-29 2010-11-10 Bath Ventures Novel interaction between staphylococcus aureus Sbi and C3d protiens
RU2016110800A (ru) * 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
JP6792847B2 (ja) * 2016-12-27 2020-12-02 国立大学法人 東京大学 ｍＲＮＡの機能化方法
MA54192A (fr) * 2018-11-07 2021-09-15 Modernatx Inc Vaccins à arn contre le cancer
AU2020321021A1 (en) * 2019-07-30 2022-03-10 Verndari, Inc. Virus-like particle vaccines
US20230302116A1 (en) * 2020-05-06 2023-09-28 Ginkgo Bioworks, Inc. VARIANT SARS-CoV-2 PROTEINS AND USES THEREOF
CA3211083A1 (en) 2021-03-04 2022-09-09 Kyle BACKMAN Compositions including sbi adjuvants and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1209455A (zh) * 1997-06-23 1999-03-03 辉瑞大药厂 编码纤溶酶原激活蛋白的dna
CN1374871A (zh) * 1999-07-21 2002-10-16 利思进药品公司 增强蛋白和肽抗原免疫原性的Fc融合蛋白
WO2002072792A2 (en) * 2001-03-13 2002-09-19 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
CN101448854A (zh) * 2006-03-22 2009-06-03 免疫生物学有限公司 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白
WO2018096089A1 (en) * 2016-11-25 2018-05-31 The University Of Bath Immunogenic compositions comprising sbi protein and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YANG JINGYUN: "A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity", NATURE, vol. 586, no. 7830, 29 July 2020 (2020-07-29), pages 572 - 577, XP037277111, DOI: 10.1038/s41586-020-2599-8 *
YANG YI，: "Utilization of staphylococcal immune evasion protein sbi as a novel vaccine adjuvant", FRONTIERS IN IMMUNOLOGY, vol. 9, 11 October 2019 (2019-10-11), pages 1 - 18 *

Also Published As

Publication number Publication date
CN119161490A (zh) 2024-12-20
KR20230154048A (ko) 2023-11-07
NZ804057A (en) 2025-07-25
JP2025026590A (ja) 2025-02-21
AU2022228575B2 (en) 2025-04-03
EP4301404A1 (en) 2024-01-10
US12343392B2 (en) 2025-07-01
US11771758B2 (en) 2023-10-03
IL305333B1 (en) 2025-06-01
US20240082388A1 (en) 2024-03-14
JP2024508683A (ja) 2024-02-28
AU2022228575A1 (en) 2023-10-12
IL305333B2 (en) 2025-10-01
AU2022228575C1 (en) 2025-10-09
BR112023017749A2 (pt) 2023-10-03
US20220362373A1 (en) 2022-11-17
AU2025205053A1 (en) 2025-07-24
IL320523A (en) 2025-06-01
IL305333A (en) 2023-10-01
CA3211083A1 (en) 2022-09-09
MX2023009995A (es) 2023-11-22
US20260061048A1 (en) 2026-03-05
WO2022187424A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
CN116916950A (zh) 包含Sbi佐剂的组合物及其使用方法
KR102833333B1 (ko) 치료적 항암 네오에피토프 백신
CN105263506A (zh) 稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法
CN111533812B (zh) 针对sars-cov-2病毒的dna疫苗及其用途
US12403190B2 (en) Coronavirus vaccine and methods of use thereof
US20240181044A1 (en) Glycan modified spike receptor binding domain nanoparticles and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine
CN113461787A (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
US20230285546A1 (en) Compositions comprising alpha-factor prepro sequence and uses thereof
TW202222821A (zh) 用於預防及/或治療covid-19之組合物及方法
KR20210114379A (ko) 융합 단백질
JP2016528176A (ja) シングルドメイン抗体ディスプレイ
US20250026793A1 (en) Chimeric betacoronavirus spike polypeptides
US9060984B2 (en) Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41
RU2850338C2 (ru) Композиции, содержащие адъюванты sbi, и способы их применения
HK40120523A (zh) 包含sbi佐剂的组合物及其使用方法
TW202500750A (zh) 用於治療痤瘡的組成物
HK1248560A1 (zh) Dna-肽组合疫苗
US12397051B2 (en) Vaccine for use against coronavirus and variants thereof
US20250270299A1 (en) Methods of using compositions comprising sbi domains
WO2026030724A1 (en) Sars-cov-2 vaccine
CN119264229A (zh) 基于SARS-CoV-2的不同奥密克戎变异型的S蛋白的疫苗和组合物
WO2023056284A1 (en) Compositions and methods for treating and preventing coronavirus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination